Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
364.65
-11.17 (-2.97%)
At close: Feb 10, 2026, 4:00 PM EST
365.03
+0.38 (0.10%)
After-hours: Feb 10, 2026, 7:52 PM EST
Amgen Revenue
In the year 2025, Amgen had annual revenue of $36.75B with 9.95% growth. Amgen had revenue of $9.87B in the quarter ending December 31, 2025, with 8.58% growth.
Revenue (ttm)
$36.75B
Revenue Growth
+9.95%
P/S Ratio
5.34
Revenue / Employee
$1,312,536
Employees
28,000
Market Cap
196.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.75B | 3.33B | 9.95% |
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
| Dec 31, 2018 | 23.75B | 898.00M | 3.93% |
| Dec 31, 2017 | 22.85B | -142.00M | -0.62% |
| Dec 31, 2016 | 22.99B | 1.33B | 6.14% |
| Dec 31, 2015 | 21.66B | 1.60B | 7.97% |
| Dec 31, 2014 | 20.06B | 1.39B | 7.43% |
| Dec 31, 2013 | 18.68B | 1.41B | 8.17% |
| Dec 31, 2012 | 17.27B | 1.68B | 10.80% |
| Dec 31, 2011 | 15.58B | 529.00M | 3.51% |
| Dec 31, 2010 | 15.05B | 411.00M | 2.81% |
| Dec 31, 2009 | 14.64B | -361.00M | -2.41% |
| Dec 31, 2008 | 15.00B | 232.00M | 1.57% |
| Dec 31, 2007 | 14.77B | 503.00M | 3.53% |
| Dec 31, 2006 | 14.27B | 1.84B | 14.79% |
| Dec 31, 2005 | 12.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
AMGN News
- 5 days ago - CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
- 6 days ago - Why Amgen Stock Is Paying Off Big For Long-Term Investors - Forbes
- 6 days ago - Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge - Seeking Alpha
- 7 days ago - Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost - WSJ
- 7 days ago - Amgen quarterly results beat Street estimates on higher sales, lower tax rate - Reuters
- 7 days ago - AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - PRNewsWire
- 7 days ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters